Superworth

Lemaitre Vascular LMAT

Medical - Instruments & Supplies, Healthcare
$81.26
+0.40%
Market cap
$1.9B
PE
28.5×
10y median 42.0×
Forward PE
n/m
not a meaningful number
Price to sales
7.1×
EV/EBIT
21.6×
Revenue, 12 months
$262.4M
+12% on a year ago
Net margin
25.0%
Free cash flow yield
4.0%

Lemaitre Vascular trades at 28.5× trailing earnings, cheaper than 89% of the last ten years. Revenue was $262.4M over the last twelve months, up 12% on a year earlier with a 25% net margin.

Charts

Financials

Income statement for LMAT, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$47.4M+22%$48.9M+19%$53.5M+14%$55.8M+11%$54.8M+16%$55.7M+14%$59.9M+12%$64.2M+15%$61M+11%$64.5M+16%$66.6M+11%$70.4M+10%
Cost of revenue$16.6M+19%$15.6M+5%$16.8M+4%$17.4M−4%$17.6M+6%$17.1M+10%$18.5M+10%$19.3M+11%$15.1M−15%$18.3M+7%$18.2M−2%$19.6M+2%
Gross profit$30.8M+23%$33.3M+28%$36.7M+19%$38.5M+20%$37.2M+21%$38.6M+16%$41.4M+13%$45M+17%$46M+24%$46.2M+20%$48.4M+17%$50.8M+13%
R&D$4.2M+22%$4.4M+22%$4.1M+6%$4.3M−5%$3.7M−13%$3.6M−17%$4.1M+0%$3.5M−17%$3M−19%$3.5M−2%$4.1M−1%$4.8M+37%
SG&A$17.4M+13%$18.7M+20%$20.7M+10%$19.8M+10%$20.4M+17%$22.1M+18%$24.7M+19%$25.3M+28%$22.7M+11%$23.8M+8%$26.6M+8%$25.5M+1%
$9.2M+49%$10.2M+47%$11.9M+51%$14.4M+52%$13.1M+43%$12.9M+26%$12.6M+6%$16.1M+12%$20.3M+55%$18.8M+47%$17.8M+41%$20.4M+26%
Interest expensen/an/a$0$0$0$205K$1.3M$1.3M$1.3M$1.3M+533%$1.3M+1%$1.3M+0%
Pre-tax income$9.8M+60%$11.3M+45%$12.8M+60%$15.5M+50%$14.6M+48%$14M+24%$14.2M+11%$18.1M+17%$22.6M+55%$20.3M+45%$19.7M+38%$22.2M+23%
$2.3M+236%$2.8M+31%$2.9M+47%$3.7M+66%$3.4M+47%$2.8M−0%$3.2M+11%$4.3M+17%$5.2M+53%$4.7M+66%$4M+24%$5.1M+20%
Net income$7.5M+38%$8.5M+50%$9.9M+64%$11.8M+46%$11.1M+49%$11.2M+32%$11M+11%$13.8M+17%$17.4M+56%$15.6M+39%$15.7M+42%$17.1M+24%
$0.33+32%$0.38+52%$0.44+63%$0.52+44%$0.49+49%$0.49+29%$0.48+9%$0.60+15%$0.75+53%$0.68+39%$0.68+42%$0.74+23%
22.5M+1%22.5M+1%22.6M+1%22.7M+1%22.8M+2%22.9M+2%22.9M+2%22.9M+1%24.4M+7%23M+0%23M+1%24.5M+7%

EPS, diluted: 5 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 16 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest Lemaitre Vascular's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
LMATLemaitre Vascular$1.9B28.5×42.0×7.1×+12%25.0%
INSPInspire Medical Systems$1.9B14.5×56.6×2.2×−0%15.0%
UFPTUFP Technologies$2.2B30.6×25.6×3.5×+7%11.4%
EYENational Vision$1.4B28.1×52.7×0.7×+8%2.5%
CDRECadre$1.3B38.9×35.9×2.0×+20%5.3%
STAAStaar Surgical$1.3B356×144×3.7×+51%1.1%
WRBYWarby Parker$2.9B341×359×3.2×+11%0.8%
ATRCAtriCure$3B285×61.7×5.3×+14%1.9%
BVSBioventus$1.1B17.1×27.1×1.9×+4%9.4%
IARTIntegra Lifesciences$1.1B80.1×46.3×0.6×+1%0.8%
IRMDIradimed$1B42.5×41.5×11.4×+11%26.8%
Peer median$1.4B40.7×49.5×2.7×+9%3.9%

More on Lemaitre Vascular

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .